Substance / Medication

Elexacaftor

SNOMED 827070004 UMLS C5139717

Overview

Active Ingredient

elexacaftor

RxNorm CUI

2256951

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Cystic fibrosis

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

NCT05743946Phase 4Completed32 enrolled

View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

A systematic review of the impact of Elexacaftor/Tezacaftor/Ivacaftor on body composition in people with cystic fibrosis.

Kinsey Laura, Winterbottom Hannah, Hudson Lydia et al. · Eur J Clin Nutr · 2025

PMID: 40121317Meta-Analysis

Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.

Edwards Steven J, Farrar Benjamin G, Ennis Kate et al. · Health Technol Assess · 2025

PMID: 40418577Meta-AnalysisFull text (PMC)

Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review.

Elzinga Femke A, Malik Paul R V, Akkerman Onno W et al. · Clin Pharmacokinet · 2025

PMID: 40399734Meta-AnalysisFull text (PMC)

Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis.

Silva Filho Luiz Vicente Ribeiro Ferreira da, Athanazio Rodrigo Abensur, Tonon Carolina Rodrigues et al. · J Bras Pneumol · 2024

PMID: 38198345Meta-AnalysisFull text (PMC)

Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with Cystic Fibrosis following liver transplantation: A systematic review.

Testa Ilaria, Indolfi Giuseppe, Brugha Rossa et al. · J Cyst Fibros · 2024

PMID: 38614868Meta-Analysis

The clinical effectiveness of elexacaftor/tezacaftor/ivacaftor (ETI) for people with CF without a F508del variant: A systematic review and meta-analysis.

Lupas Daniel, Chou Frank Y, Hakani Mohammad Abdullah Al et al. · J Cyst Fibros · 2024

PMID: 39048464Meta-Analysis

Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.

Xu Wenye, Wu Ting, Zhou Zijing et al. · Front Pharmacol · 2023

PMID: 38186649Meta-AnalysisFull text (PMC)

Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.

Keating Claire, Yonker Lael M, Vermeulen François et al. · Lancet Respir Med · 2025

PMID: 39756424RCTFull text (PMC)

The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study.

Donaldson Scott H, Corcoran Timothy E, Pilewski Joseph M et al. · J Cyst Fibros · 2024

PMID: 38355350RCTFull text (PMC)

Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis.

Mayer-Hamblett Nicole, Gifford Alex H, Kloster Margaret et al. · Ann Am Thorac Soc · 2024

PMID: 39041864RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Elexacaftor (substance)
SNOMED CT: 827070004
UMLS CUI: C5139717
RxNorm CUI: 2256951

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.